Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL

Immunoglobulin E (IgE) plays a critical role in the allergen-initiated inflammatory pathway and thus serves as a viable therapeutic target in allergic or IgE-mediated diseases such as asthma. Omalizumab, an anti-IgE biologic, has been approved in the United States (US, 2003) and in the European Unio...

Descripción completa

Detalles Bibliográficos
Autores principales: Menzella, Francesco, Just, Jocelyne, Sauerbeck, Inessa Schwab, Mailaender, Claudia, Saccheri, Fabiana, Thonnelier, Celine, Jaumont, Xavier, Mala, Laurence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2023
Materias:
Invited Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276275/
https://www.ncbi.nlm.nih.gov/pubmed/37332525
http://dx.doi.org/10.1016/j.waojou.2023.100787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276275/
https://www.ncbi.nlm.nih.gov/pubmed/37332525
http://dx.doi.org/10.1016/j.waojou.2023.100787

Ejemplares similares